Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.36 |
| ▸ | PDE4A | P27815 | 4/20 | 0.33 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18986848 | 0.82 | CYP51A1 (0.33) | CYP51A1PDE4ANOX1PNMTCYP2C9 | |
| SCHEMBL18986772 | 0.82 | PDE4A (0.33) | CYP51A1PDE4ANOX1PNMTCYP2C9 | |
| SCHEMBL27965915 | 0.77 | GABRP (0.41) | CYP51A1CYP2C9CA1CA2CA9 | |
| SCHEMBL28097360 | 0.74 | RAD51 (0.32) | RAD51 | |
| SCHEMBL24208362 | 0.73 | SLC6A4 (0.32) | — | |
| SCHEMBL15426999 | 0.72 | UHRF1 (0.45) | CYP51A1PDE4ANOX1CA1CA2 | |
| SCHEMBL18986919 | 0.70 | MEN1 (0.55) | — | |
| SCHEMBL28267926 | 0.68 | LOXL2 (0.43) | CYP51A1PDE4ANOX1CA1CA2 | |
| SCHEMBL511705 | 0.68 | LOXL2 (0.40) | — | |
| SCHEMBL17208761 | 0.67 | HTR1A (0.40) | CYP51A1PDE4ANOX1PNMTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180355441-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2018-12-13 | — | — | US | disclosed |
| EP-3390420-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | Centre National De La Recherche Scientifique (FR) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102934-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180355441-A1 | VISUAL DETECTION OF PLATINATED DNA LESIONS FROM A CLICKABLE CISPLATIN PROBE USED AS DIAGNOSTIC TOOL OR TO IDENTIFY SYNERGISTIC TREATMENTS | ERCC5, ERCC1, ERCC4 | CYP51A1 4829/4885PDE4A 4279/4885NOX1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.